Ceramide NanoLiposome
Phase 1Small molecule
Ceramide NanoLiposome is one of 3 small molecule programs targeting Acute Myeloid Leukemia, in Relapse. It is currently in Phase 1.
1
Indications
2
Total Trials
1
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2 competitors in Acute Myeloid Leukemia, in Relapse
#DrugCompanyPhaseTrials
1Xospata
AstellasPhase 1
Iadademstat
OOryzon Genomics S.A.
Phase 1
Ceramide NanoLiposome
KKeystone Nano, Inc
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ceramide NanoLiposome. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- KKeystone Nano, Inc